Simplify Logo

Full-Time

Director – Manufacturing Cell Therapy

Confirmed live in the last 24 hours

Adicet Bio, Inc

Adicet Bio, Inc

51-200 employees

Develops allogeneic gamma delta T cell therapies

Hardware
Biotechnology
Healthcare

Compensation Overview

$184k - $254kAnnually

Senior, Expert

San Carlos, CA, USA

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Requirements
  • Bachelor of Science and at least 10 years of experience or Master of Science and at least eight years of experience or Ph.D. and at least six years of experience.
  • Manufacturing experience in biologics operations required, with viral vector and cell therapy experience much preferred.
  • Highly familiar with all of the following manufacturing aspects: aseptic processing, expansion and differentiation of CAR-T products (allogenic and/or autologous), generation of viral vectors in adherent cultures, and formulation of cellular therapeutics.
  • Understanding of cGMP Directives, industry guidelines and applicable agency regulation (FDA, EMA, etc.) particularly as they relate to cell and gene therapy.
  • Strong leadership skills, ability to communicate and partner well with all levels of staff, to lead and motivate with emphasis on compliance and continuous improvement and to resolve conflicts.
  • Ability to monitor and control processes using data trending and/or statistical process control.
  • Proven ability to trouble shoot and resolve issues.
  • Effectively employ all methods of communication (oral, written, presentation) to provide ongoing communication to employees or teams.
Responsibilities
  • Lead production team for viral vector and cell therapy Current Good Manufacturing Practices manufacturing (cGMP) and cGMP supply chain.
  • Ensure timely onboarding of personnel to maximize training opportunities and to deliver all process and/or facility validation requirements.
  • Work with site teams to integrate with and influence established site systems as needed to implement new vector and cell therapy production operations.
  • Create visibility to site integration activities and/or gaps and establish processes for site integration with production operations (or vice versa).
  • Lead all manufacturing aspects of tech transfer into manufacturing including, but not limited to, assessment of new product requirements against processes, generation of product specific documentation, supporting the introduction of new equipment, raw materials and/or consumables, determine safety implications if any and training of personnel.
  • Lead qualification of processes as needed for production and to ensure readiness for product introduction.
  • Develop manufacturing area plan and systems/processes that support both the project and operationalizing the manufacturing facility.
  • Manage manufacturing activities for viral vector and cell therapy, including cGMP aseptic qualification, in support of manufacturing and formulation of viral vectors as drug substance and of cell therapeutics as drug products.
  • Adhere to clinical and launch supply chain targets by meeting or exceeding monthly and annual production output demand.
  • Demonstrate commitment to safety by driving a safety culture and engaging in all safety initiatives.
  • Be responsible for department cost center by reviewing monthly costs.
  • Prepare and adhere to production output and operating budgets for department.
  • Continuously seek opportunities for improving overall compliance and reduce discrepancies.
  • Partner with Quality to implement and manage phase appropriate systems/processes/procedures to meet cGMP manufacturing requirements against regulatory standards in various regions (US/EU/etc.).
  • Track adverse trends and ensure they are addressed quickly and effectively.
  • Provide direction and/or act as escalation point for unresolved deviations/non conformances.
  • Partner with Quality and Engineering representatives to implement effective corrective and preventative actions (CAPAs) to mitigate reoccurrence.

Adicet Bio develops cancer therapies using allogeneic gamma delta T cell therapies, which are immune cells designed to target and destroy cancer cells. Their approach utilizes donor-derived cells that are readily available, allowing for faster treatment compared to traditional methods that require a patient's own cells. The company focuses on serving healthcare providers, hospitals, and research institutions involved in cancer treatment. Adicet Bio's business model includes developing and commercializing its proprietary therapies, generating revenue through product sales and licensing agreements. A recent merger with resTORbio aims to enhance their technology and accelerate development. With significant funding, Adicet Bio is positioned to improve cancer treatment outcomes through its unique immunotherapy approach.

Company Stage

IPO

Total Funding

$243.6M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

-3%

1 year growth

-1%

2 year growth

39%
Simplify Jobs

Simplify's Take

What believers are saying

  • Adicet Bio's strong financial position, with $247.6 million in cash and cash equivalents, provides a solid foundation for continued R&D and clinical trials.
  • The promising preclinical data on ADI-270 and the initiation of multiple Phase 1 trials highlight the company's robust pipeline and potential for breakthrough therapies.
  • The company's strategic focus on both solid and hematological cancers, as well as autoimmune diseases, increases the likelihood of successful treatments and market adoption.

What critics are saying

  • The clinical and regulatory landscape for new cancer therapies is highly competitive and uncertain, posing risks to Adicet Bio's market entry and adoption.
  • The reliance on successful clinical trial outcomes for ADI-001 and ADI-270 introduces significant uncertainty and potential delays in commercialization.

What makes Adicet Bio, Inc unique

  • Adicet Bio's use of allogeneic gamma delta T cells offers an 'off-the-shelf' solution, providing faster and potentially more effective cancer treatments compared to autologous therapies.
  • The company's focus on both cancer and autoimmune diseases broadens its market reach and potential impact, unlike competitors who may focus solely on one area.
  • Adicet Bio's recent merger with resTORbio and significant funding rounds, including an $80 million Series B, bolster its R&D capabilities and accelerate its path to commercialization.